TrialSignal transduction and targeted therapy2024

A phase II clinical trial of toripalimab in advanced solid tumors with polymerase epsilon/polymerase delta (POLE/POLD1) mutation.

Ying Jin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.